Evidence map›Paper›PMID 23860248›Full record

SynthesisCritical care medicine2013

Blood purification and mortality in sepsis: a meta-analysis of randomized trials.

Feihu Zhou, Zhiyong Peng, Raghavan Murugan, John A Kellum

3 registry-linked trialsAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Critical care medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 77 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 9 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04057872 phase1completednot on this mapstarted 2020, after this paper: background citation

PILOT STUDY in the Use of Therapeutic Plasma Exchange in Adult Patients With Severe Sepsis

TypeinterventionalSponsorAlberta Health Services, CalgaryRan2020 to 2024Enrolled17ConditionsSeptic ShockArmsTherapeutic plasma exchange
NCT04884854 completednot on this mapstarted 2019, after this paper: background citation

Early Efferon LPS Hemoperfusion Through Hypercrosslinked Styrene-divinylbenzene Copolymer With Immobilized LPS-selective Ligand for Treatment of Patients With Septic Shock

TypeobservationalSponsorEfferon JSCRan2019 to 2020Enrolled9ConditionsSeptic ShockArmsEfferon LPS
NCT06989892 narecruitingnot on this mapstarted 2024, after this paper: background citation

Comparing Super High-flux and High-flux Dialyzer Performance Among Hemodialysis Patient With Sepsis : a Randomized Control Trial

TypeinterventionalSponsorNavamindradhiraj UniversityRan2024 to 2026Enrolled202ConditionsThe Efficacy and Safety for Super High-flux Dialyzer in Case of Sepsis in ESKD, End Stage Kidney Disease (ESRD), SepsisArmsSuper High-flux dialyzer (Elisio 19HDx), High-flux dialyzer (Elisio 19H)
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 9 syntheses or guidelines pooled it, 188 citations in OpenAlex.

  1. Pooled it
  2. [S3 guideline on sepsis-prevention, diagnosis, therapy, and follow-up care-update 2025].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025
    Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. [S3 Guideline Sepsis-prevention, diagnosis, therapy, and aftercare : Long version].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2020
    Guideline
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Trial
  11. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2017
    Trial
  12. Trial
  13. Article
  14. Article
  15. Retrospective evaluation of efficacy of CytoSorbWorld journal of critical care medicine · 2025
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Feihu ZhouDepartment of Critical Care Medicine, The Clinical Research, Investigation, and Systems Modeling of Acute illness (CRISMA) Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Zhiyong Peng
Raghavan Murugan
John A Kellum
University of Pittsburgh · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
University of Pittsburgh Clinical and Translational Science InstitutionKL2RR024154 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$22.2M
Systems Engineering of Pheresis Intervention for SepsisR01HL080926 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KELLUM, JOHN A · 2005 to 2009
$6.8M
NCATS NIH HHS UL1 TR000005NCRR NIH HHS 2KL2RR024154-06NCRR NIH HHS KL2 RR024154NHLBI NIH HHS R01 HL080926NHLBI NIH HHS R01HL080926
6 · The paper itself

Abstract

objectivesAlthough blood purification improves outcomes in animal studies of sepsis, results of clinical trials have been mixed. We conducted a systematic review and meta-analysis of randomized trials to determine the association between various blood purification techniques and all-cause mortality in humans with sepsis. DATA SOURCES: We searched for relevant studies in MEDLINE, EMBASE, and the Cochrane Library database from January 1966 to May 2012. STUDY SELECTION: Inclusion required a diagnosis of sepsis and comparison of blood purification techniques including hemofiltration, hemoperfusion, plasma exchange, or hemodialysis with no blood purification (control group). DATA EXTRACTION: Two authors independently selected studies and extracted data. Summary statistics, risk ratios, and CIs were calculated using random-effects modeling. Study quality was assessed using Jadad score, and publication bias was assessed using funnel plots and Egger's statistic. DATA SYNTHESIS: Overall, blood purification decreased mortality compared with no blood purification (35.7% vs 50.1%; risk ratio, 0.69 [95% CI, 0.56-0.84]; p<0.001; 16 trials, n=827). However, these results were driven mainly by hemoperfusion (risk ratio, 0.63 [95% CI, 0.50-0.80]; p<0.001; 10 trials, n=557) and plasma exchange (risk ratio, 0.63 [95% CI, 0.42-0.96]; p=0.03; two trials, n=128). Pooling of all trials of blood purification for treatment of sepsis was no longer associated with lower mortality (risk ratio, 0.89 [95% CI, 0.71-1.13]; p=0.36; eight trials, n=457) after excluding trials using polymyxin B hemoperfusion.

conclusionsBlood purification techniques including hemoperfusion, plasma exchange, and hemofiltration with hemoperfusion were associated with lower mortality in patients with sepsis. These results were mainly influenced by studies using polymyxin B hemoperfusion from Japan.

Indexed as

Randomized Controlled Trials as TopicCause of DeathHumansSepsisSorption Detoxification

Identifiers

PMID23860248
PMCPMC3758418
OpenAlexW2089094816

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.